QNRX
Quoin Pharmaceuticals, Ltd. NASDAQ$6.36
Mkt Cap $3.7M
52w Low $5.20
3.2% of range
52w High $41.80
50d MA $7.25
200d MA $9.79
P/E (TTM)
0.0x
EV/EBITDA
233.0x
P/B
0.5x
Debt/Equity
0.0x
ROE
-120.5%
P/FCF
-0.0x
RSI (14)
—
ATR (14)
—
Beta
1.82
50d MA
$7.25
200d MA
$9.79
Avg Volume
100.2K
About
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | AMC | -6.42 | -14.80 | -130.5% | 7.57 | -2.1% | -15.3% | -17.0% | -12.8% | -19.9% | -7.3% | — |
| Nov 6, 2025 | AMC | -6.36 | -6.71 | -5.5% | 8.57 | -0.9% | +5.1% | -5.0% | +34.3% | +41.1% | +56.6% | — |
| Aug 7, 2025 | AMC | -6.83 | -6.28 | +8.1% | 6.91 | +1.2% | +3.5% | +2.0% | +3.9% | +3.9% | +5.6% | — |
| May 13, 2025 | AMC | -3.85 | -6.50 | -68.8% | 6.36 | +38.8% | +20.3% | +21.1% | +21.1% | +25.6% | +33.2% | — |
| Mar 13, 2025 | AMC | -0.50 | -12.24 | -2348.0% | 10.32 | +0.0% | +3.1% | +3.5% | +0.0% | +1.7% | -1.6% | — |
| Nov 7, 2024 | AMC | -15.38 | -16.43 | -6.8% | 24.25 | +1.0% | -3.3% | -7.6% | -10.5% | -10.6% | -12.4% | — |
| Aug 8, 2024 | AMC | -26.22 | -13.64 | +48.0% | 18.34 | -6.5% | -5.3% | +1.7% | -0.9% | -8.4% | -4.6% | — |
| May 9, 2024 | AMC | -0.76 | -38.81 | -5006.6% | 27.83 | -0.6% | -2.8% | -0.8% | -2.2% | -2.4% | -2.4% | — |
| Mar 13, 2024 | AMC | -82.87 | -72.73 | +12.2% | 40.60 | -3.4% | -13.8% | -17.5% | -21.6% | -23.3% | -22.4% | — |
| Nov 8, 2023 | AMC | -83.92 | -68.18 | +18.8% | 154.88 | +7.1% | -8.3% | -12.5% | -11.0% | -4.0% | -4.0% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 15 | Maxim Group | Maintains | Buy → Buy | — | $35.00 | $36.05 | +3.0% | -4.3% | -9.0% | -11.0% | -10.0% | -10.0% |
| Sep 7 | Alliance Global Partners | Maintains | Buy → Buy | — | $1394.40 | $1663.20 | +19.3% | +17.8% | +9.6% | +12.0% | +28.3% | +18.4% |
| May 6 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $4247.25 | $4830.00 | +13.7% | -2.3% | -19.5% | -22.7% | -29.3% | -30.8% |
| Jan 7 | Maxim Group | Maintains | Buy → Buy | — | $9135.00 | $10132.50 | +10.9% | +19.5% | +6.3% | +10.3% | +6.3% | -4.6% |
| Dec 15 | JMP Securities | Maintains | Market Outperform → Outperform | — | $16695.00 | $26722.50 | +60.1% | -12.6% | -24.5% | -32.7% | -41.8% | -32.7% |
Data updated apr 26, 2026 9:33pm
· Source: massive.com